Anal Cancer Recurrence: What to Ask

This page is for people whose anal cancer did not fully clear after chemoradiation, or came back later. It explains when response is judged, where cancer can return, what salvage treatment involves, and what to ask your team.

Most anal cancer is treated without an operation. Chemoradiation is the standard for stage I, II and III disease. The usual pair is fluorouracil and mitomycin, with beam radiation. Capecitabine can replace fluorouracil. Cisplatin can replace mitomycin.

That approach leaves a problem behind. Radiated tissue does not clear on a schedule.

NCI is direct about it. The best time to judge a complete response is generally after 26 weeks. Delayed responses are seen. So the mark is six months, not six weeks.

This one fact changes many talks. A firm area felt at week 8 is not proof of failure. It may still clear. Acting too early risks an operation that was never needed.

Three patterns exist. They lead to three different plans.

• Local means the anal canal itself, at the site first treated.
• Regional means lymph nodes, usually in the groin or the pelvis.
• Distant means outside the pelvis.

The first question a team answers is which one this is. The second is what that area already received. NCI's rule for local return is to use the other treatment. Surgery after radiation. Radiation after surgery. Whether a groin node area sat inside the first radiation field decides if more radiation is even possible.

Before any plan is made, the team needs to be sure the cancer is really there. Diagnosis here is physical as much as radiological. A digital rectal exam and anoscopy look at the site directly. Groin nodes are felt by hand. Imaging follows.

Tissue settles it. Salvage surgery is not a small operation. So the usual order confirms disease first.

There is a second reason to look closely. NCI links anal cancer with human papillomavirus (HPV) infection. The same field can grow new precancerous change rather than true recurrence. High-resolution anoscopy answers a different question from a recurrence scan.

Salvage treatment means treatment given after the first approach has left disease behind, or the cancer has returned. NCI names the standard salvage plainly. For gross or microscopic residual disease after chemoradiation, that has been abdominoperineal resection. The operation removes the anus and rectum. It leaves a permanent colostomy.

There is an alternative worth naming. NCI notes that salvage chemoradiation may avoid permanent colostomy for some people. That means fluorouracil and cisplatin plus a radiation boost. It applies to residual tumor after first-line nonoperative treatment. More chemotherapy alone, or immunotherapy, are also listed.

Whether it is possible depends on two things: how much radiation was already given, and how small the residual disease is. This is a real question, not a courtesy one.

The trial data explain why colostomy-free survival is the number people track. In RTOG 9811, 5-year colostomy-free survival was 71.9% with mitomycin. It was 65% with cisplatin. In an earlier trial, adding mitomycin raised 4-year colostomy-free survival from 59% to 71%.

Distant disease follows a separate track. The evidence there changed direction.

The randomized phase II InterAAct trial tested two regimens. One was carboplatin at AUC 5 with weekly paclitaxel. The other was infusional fluorouracil with bolus cisplatin. At a median 25.3 months, median overall survival was 20 months with carboplatin and paclitaxel. It was 12.3 months with cisplatin and fluorouracil. Carboplatin and paclitaxel became the backbone in later trials.

Checkpoint drugs showed activity too. The phase II NCI9673 trial gave nivolumab by drip every 2 weeks to 37 patients, at the weight-based amount the protocol specified. The overall response rate was 24%. Two responses were complete.

One thing on this page is absent from the NCI summary. That is worth saying plainly.

The FDA has approved retifanlimab, a PD-1 blocking antibody sold as Zynyz. Its label covers two uses in this disease. First, with carboplatin and paclitaxel, as first-line treatment. That applies to inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal. Second, on its own, after progression on platinum chemotherapy or intolerance to it. It is given as a drip lasting about 30 minutes, either every 4 weeks or every 3 weeks. The oncology team picks the schedule and works out the amount. So there is nothing here for you to measure.

NCI's own drug page describes both uses. NCI's anal cancer PDQ summary does not mention the drug at all. That summary was last updated on February 12, 2025. Both pages come from the same institution. When a treatment summary and a current label disagree, the label is the newer document.

Fluorouracil and capecitabine are broken down by one enzyme. The DPYD gene encodes it. NCI estimates that 1% to 2% of people carry harmful variants in that gene.

The consequence is serious. People with the DPYD*2A variant may have severe toxicity from these drugs. It can be life-threatening, and sometimes fatal. Depending on the genotype found, the prescribing team may avoid the drug altogether or start at a reduced amount that they calculate.

NCI states the trade-off honestly. Testing costs less than $200. Insurance coverage varies, because no national guideline exists. Results may take 2 weeks. In an urgent case that delay may not be acceptable. In a planned salvage regimen it often is.

The useful questions here are about timing and anatomy:

• How many weeks has it been since chemoradiation ended?
• Has a biopsy confirmed the disease?
• Which of the three patterns (local, regional, or distant) applies?
• Did the involved area sit inside the earlier radiation field?
• Could salvage chemoradiation stand in for abdominoperineal resection?
• Has a tumor board reviewed the case? Anal cancer is uncommon, so most centers see few of them.

For related ground, see anal cancer, getting a second opinion, and fear of recurrence.

• Call 911 or go to an emergency department if rectal bleeding is heavy and will not stop, or if severe abdominal pain comes with vomiting and you are passing neither stool nor gas. Do not drive yourself.
• Call your care team at once, day or night, if a temperature of 100.4°F (38°C) or higher turns up while you are taking fluorouracil or capecitabine. CDC calls a fever during chemotherapy a medical emergency, because these drugs strip out the white cells that hold an infection back. If nobody picks up within a few minutes, go to an emergency department and say you are on chemotherapy.
• Call your care team right away if you are taking fluorouracil or capecitabine and get diarrhea, sores in the mouth and throat, chills, or swelling, pain, redness or peeling on the palms and soles. MedlinePlus says to call the doctor immediately or get emergency care for these. In the small group carrying a harmful DPYD variant they can turn severe fast, which is the point of the test described above.
• Call your care team right away if you are on retifanlimab and develop new or worse diarrhea, blood or mucus in the stool, severe belly pain, a cough, shortness of breath or chest pain, yellowing of the skin or eyes, or a rash that blisters or peels. The drug's Medication Guide says to call or see your provider right away for new or worsening signs like these.
• Call your care team within a day or two if pain in the anal area, bleeding, or a change in how you pass stool is new or steadily worsening after chemoradiation ended.

• NCI PDQ — Anal Cancer Treatment (Health Professional Version)
• NCI PDQ — Anal Cancer Treatment (Patient Version)
• NCI — Retifanlimab-dlwr
• DailyMed — ZYNYZ (retifanlimab-dlwr) injection prescribing information
• MedlinePlus — Fluorouracil Injection
• FDA — Retifanlimab-dlwr approval for squamous cell carcinoma of the anal canal
• CDC — Fever during chemotherapy
• MedlinePlus — Gastrointestinal bleeding
• MedlinePlus — Abdominal pain